✦ LIBER ✦

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

✍ Scribed by C. Levy; J. A. Peter; D. R. Nelson; J. Keach; J. Petz; R. Cabrera; V. Clark; R. J. Firpi; G. Morelli; C. Soldevila-Pico; K. Lindor

Book ID: 108606134
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 146 KB
Volume: 33
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2010.04512.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Atorvastatin in patients with primary bi

Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid

✍ Tatjana Stojakovic; Csilla Putz-Bankuti; Günter Fauler; Hubert Scharnagl; Martin 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB 👁 1 views

Statin therapy may target both hypercholesterolemia and cholestasis in primary biliary cirrhosis (PBC). However, little is known about the efficacy and safety of statins in PBC. The aim of this single-center study was therefore to prospectively examine the effects of atorvastatin on serum markers of

Biochemical and immunologic effects of r

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

✍ Masanobu Tsuda; Yuki Moritoki; Zhe-Xiong Lian; Weici Zhang; Katsunori Yoshida; K 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 904 KB

The combination of ursodeoxycholic acid

The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study

✍ Keith D. Lindor; E. Rolland Dickson; Roberta A. Jorgensen; Monte L. Anderson; Ru 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 553 KB

Ursodeoxycholic acid (UDCA) and methotrexate (MTX) have both been proposed as treatments for patients with primary biliary cirrhosis (PBC). It has been suggested that a combination of the two drugs may offer advantages over either used separately. In this pilot study, we sought to evaluate the safet

Early biochemical response to ursodeoxyc

Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis

✍ Nobuaki Azemoto; Masanori Abe; Yosuke Murata; Yoichi Hiasa; Maho Hamada; Bunzo M 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 215 KB

Additive improvement induced by bezafibr

Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid

✍ Yasuto Takeuchi; Fusao Ikeda; Shin-ichi Fujioka; Toshiyuki Takaki; Toshiya Osawa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 928 KB

Oral budesonide in the treatment of pati

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

✍ Paul Angulo; Roberta A. Jorgensen; Jill C. Keach; E. Rolland Dickson; Coleman Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC). However, some patients show an incomplete response to UDCA therapy. Treatment with corticosteroids may be of benefit although at the expense of systemic side effects. Budesonid